Nagareyama, Japan

Akiko Ariga

This inventor holds 1 USPTO granted patent. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 1980.


% Patents Active = 100.0

Average Co-Inventor Count = 13.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1980

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Akiko Ariga: Innovator in Terephthalic Acid Monoamide Derivatives

Introduction

Akiko Ariga is a prominent inventor based in Nagareyama, Japan. She has made significant contributions to the field of chemistry, particularly in the development of terephthalic acid monoamide derivatives. Her innovative work has led to advancements in pharmaceutical applications.

Latest Patents

Akiko Ariga holds 1 patent related to her research. The patent focuses on terephthalic acid monoamide derivatives and outlines a process for preparing these compounds. The derivatives are characterized by a specific formula where R represents a straight- or branched-chain lower alkyl group. The patent also discusses the potential use of these derivatives as anti-allergic agents.

Career Highlights

Throughout her career, Akiko has been associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company. Her work has been instrumental in developing new therapeutic agents that can improve patient outcomes. Akiko's dedication to research and innovation has established her as a key figure in her field.

Collaborations

Akiko has collaborated with notable colleagues, including Kazuo Igusa and Toshichika Ogasawara. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise.

Conclusion

Akiko Ariga's contributions to the field of chemistry, particularly in the area of terephthalic acid monoamide derivatives, highlight her innovative spirit and commitment to advancing pharmaceutical science. Her work continues to inspire future research and development in this important area.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…